Welcome to our dedicated page for Edwards Lifesciences news (Ticker: EW), a resource for investors and traders seeking the latest updates and insights on Edwards Lifesciences stock.
Edwards Lifesciences Corp (NYSE: EW) is a pioneering global entity in the realm of heart valve technology and hemodynamic monitoring. Headquartered in Irvine, California, the company has a robust presence across North America, Europe, Japan, Latin America, and Asia, employing approximately 6,400 individuals worldwide. Edwards Lifesciences specializes in developing medical devices and technologies that address structural heart disease and critical care monitoring, aiming to save and enhance patients' lives.
Originating from a spin-off of Baxter International in 2000, Edwards Lifesciences has cemented its position as a leader in manufacturing and marketing advanced medical equipment. The company's core products include surgical tissue heart valves, transcatheter valve technologies, surgical clips, and catheters. These innovations have positioned Edwards Lifesciences as a key player in the medical field, particularly in the areas of heart valve replacement and repair.
Edwards Lifesciences generates about 55% of its sales from international markets, showcasing its extensive global reach. The company's commitment to innovation is evident in its continuous development of technologies that monitor vital signs in critical care settings, ensuring that patients improve their quality of life.
Recently, Edwards Lifesciences announced a significant transaction with Becton, Dickinson and Company (BD), where BD will acquire Edwards' Critical Care product group for $4.2 billion in cash. This acquisition is expected to unlock new value creation opportunities and enhance BD's portfolio of smart connected care solutions. The Critical Care unit, known for its advanced patient monitoring solutions and AI-driven technologies, will operate as a separate business unit within BD's Medical segment, maintaining its base in Irvine.
The transaction is anticipated to be immediately accretive to all key financial measures, with a strong focus on revenue growth, adjusted gross and operating margins, and adjusted earnings per share. It highlights Edwards Lifesciences' strategic intent to drive innovation and value through partnerships and strategic acquisitions.
Edwards Lifesciences reported Q1 2022 results with sales of $1.34 billion, reflecting a 10% growth. TAVR sales rose 11% to $881 million. The company reaffirmed its full-year guidance for low double-digit growth despite challenges from the Omicron variant. Adjusted EPS stood at $0.60. The surgical mitral tissue valve MITRIS RESILIA received U.S. approval. The company repurchased approximately $400 million of stock. Outlook remains optimistic for 2022, with expected sales between $5.5 to $6.0 billion.
Edwards Lifesciences (NYSE: EW) will announce its operating results for Q1 2022 after market close on April 26, 2022. A conference call to discuss these results is scheduled for 5:00 p.m. ET on the same day. Edwards Lifesciences is recognized for its innovations in structural heart disease and critical care monitoring. Investors can participate by dialing (877) 704-2848 or (201) 389-0893, and the call will also be streamed live on the company’s Investor Relations webpage.
Edwards Lifesciences (NYSE: EW) has received FDA approval for the MITRIS RESILIA valve, a tissue valve designed for mitral valve replacement. This innovation features a saddle-shaped sewing cuff and a low-profile frame to minimize obstruction, facilitating future transcatheter interventions. The RESILIA tissue used in the valve has undergone extensive clinical trials, demonstrating its integrity and longevity potential. The valve is already approved in Japan, Canada, and other regions, expanding Edwards' portfolio of surgical heart valve products.
Edwards Lifesciences (NYSE: EW) reported a 19% increase in sales for 2021, totaling $5.2 billion, with Q4 sales reaching $1.33 billion, up 12%. TAVR sales hit $872 million in Q4, also up 12%. The company completed pivotal trials and received FDA approval for new products. The adjusted EPS for 2021 was $2.22, a 19% rise year-over-year. For 2022, the company expects sales between $5.5 to $6 billion and adjusted EPS of $2.50 to $2.65. Edwards anticipates significant growth in transcatheter therapies, predicting a global TAVR market expansion to $10 billion by 2028.
Edwards Lifesciences (NYSE: EW) will announce its operating results for the quarter ended December 31, 2021, after market close on January 26, 2022. The company will host a conference call at 5:00 p.m. ET that same day to discuss these results. Investors can participate by dialing (877) 704-2848 or (201) 389-0893. The call will also be available live and archived on the Investor Relations section of the Edwards website.
IRVINE, Calif., Jan. 5, 2022 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW) will participate in the J.P. Morgan Healthcare Conference on January 10, 2022. CEO Michael A. Mussallem is set to present virtually at 11:15 a.m. ET. A live webcast will be available on the company's investor relations website, along with an archived version later that day. Edwards Lifesciences is known for its innovations in structural heart disease and critical care monitoring.
Edwards Lifesciences has received FDA approval for the SAPIEN 3 transcatheter valve with Alterra adaptive prestent, enhancing treatment options for patients with severe pulmonary regurgitation. This innovative system combines the SAPIEN 3 valve and Alterra prestent to cater to variations in right ventricular outflow tract morphology, improving patient outcomes and reducing the need for multiple surgeries. The approval targets pediatric and adult patients requiring surgical valve replacement and is expected to significantly enhance quality of life.
Edwards Lifesciences hosted its annual investor conference, reaffirming its 2021 financial guidance and presenting a robust growth strategy for 2022. The company projects global sales of $5.5 - $6.0 billion, with TAVR sales expected to be $3.7 - $4.0 billion, reflecting a 12-15% growth. Edwards aims for substantial long-term expansion, targeting a global market opportunity of nearly $20 billion by 2028 across four product groups. With a focus on innovation and R&D, 17-18% of sales are allocated to research, underpinning confidence in double-digit growth ahead.
Edwards Lifesciences (NYSE: EW) announced promising results from the TRISCEND study, focusing on the EVOQUE transcatheter tricuspid valve replacement system. The six-month follow-up of 56 patients showed a significant reduction in tricuspid regurgitation (TR), with 100% achieving none/trace or mild TR. Other outcomes included 89% of patients in NYHA Class I or II and a survival rate of 96%. These findings were presented at the 33rd Transcatheter Cardiovascular Therapeutics conference, highlighting the potential of the EVOQUE system in treating high-risk patients.
Edwards Lifesciences (NYSE: EW) announced a cost-effectiveness analysis from the PARTNER 3 trial, revealing that transcatheter aortic valve replacement (TAVR) with the SAPIEN 3 valve is an economically dominant treatment compared to traditional surgery. The analysis, presented at the 33rd TCT symposium, indicated that TAVR could save over $2,000 per patient due to reduced hospital stays and follow-up costs, while improving quality-adjusted life expectancy. With a 95% probability of being highly cost-effective, this finding empowers both patients and cardiologists in treatment decisions.
FAQ
What is the current stock price of Edwards Lifesciences (EW)?
What is the market cap of Edwards Lifesciences (EW)?
What does Edwards Lifesciences Corp specialize in?
Where is Edwards Lifesciences headquartered?
How many employees does Edwards Lifesciences have?
What percentage of Edwards Lifesciences' sales come from international markets?
What was the significant recent transaction involving Edwards Lifesciences?
What products does Edwards Lifesciences offer?
When was Edwards Lifesciences spun off from Baxter International?
What is the primary goal of Edwards Lifesciences' innovative technologies?
How will the recent transaction with BD impact Edwards Lifesciences?
What makes Edwards Lifesciences a leader in its field?
